Your browser doesn't support javascript.
loading
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy.
Voltin, Conrad-Amadeus; Gödel, Philipp; Beckmann, Laura; Heger, Jan-Michel; Kobe, Carsten; Kutsch, Nadine; Borchmann, Peter; Dietlein, Markus; Herrmann, Ken; Stelljes, Matthias; Rahbar, Kambiz; Lenz, Georg; Reinhardt, H Christian; Teichert, Marcel; Noppeney, Richard; Albring, Jörn C; Seifert, Robert; von Tresckow, Bastian; Flossdorf, Sarah; Hanoun, Christine.
Afiliação
  • Voltin CA; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Gödel P; First Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Beckmann L; Cologne Essen Lymphoma Working Group (CLWG), Cologne and Essen, Germany.
  • Heger JM; First Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Kobe C; Cologne Essen Lymphoma Working Group (CLWG), Cologne and Essen, Germany.
  • Kutsch N; First Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Borchmann P; Cologne Essen Lymphoma Working Group (CLWG), Cologne and Essen, Germany.
  • Dietlein M; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Herrmann K; First Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Stelljes M; Cologne Essen Lymphoma Working Group (CLWG), Cologne and Essen, Germany.
  • Rahbar K; First Department of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Lenz G; Cologne Essen Lymphoma Working Group (CLWG), Cologne and Essen, Germany.
  • Reinhardt HC; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Teichert M; Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Noppeney R; Department of Medicine A-Hematology, Oncology, and Pneumology, West German Cancer Center (WTZ), University Hospital Münster, University of Münster, Germany.
  • Albring JC; Department of Nuclear Medicine, University Hospital Münster, University of Münster, Germany.
  • Seifert R; Department of Medicine A-Hematology, Oncology, and Pneumology, West German Cancer Center (WTZ), University Hospital Münster, University of Münster, Germany.
  • von Tresckow B; Cologne Essen Lymphoma Working Group (CLWG), Cologne and Essen, Germany.
  • Flossdorf S; Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Hanoun C; Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Hemasphere ; 7(1): e817, 2023 Jan.
Article em En | MEDLINE | ID: mdl-36698613
ABSTRACT
The introduction of chimeric antigen receptor (CAR) T-cell therapy has led to a fundamental shift in the management of relapsed and refractory large B-cell lymphoma. However, our understanding of risk factors associated with non-response is still insufficient and the search for predictive biomarkers continues. Some parameters measurable on 18F-fluorodeoxyglucose positron emission tomography (PET) may be of additional value in this context. A total of 47 individuals from three German university centers who underwent re-staging with PET prior to CAR T-cell therapy were enrolled into the present study. After multivariable analysis considering tumor characteristics and patient factors that might affect progression-free survival (PFS), we investigated whether metabolic tumor volume (MTV) or maximum standardized uptake value (SUVmax) further improve risk stratification. Their most suitable cut-offs were determined by Cox and logistic regression. Forward selection identified extra-nodal disease as the most predictive factor of those routinely available, and we found it to be associated with significantly inferior overall survival after CAR T-cell treatment (P = 0.012). Furthermore, patients with MTV and SUVmax higher than the optimal threshold of 11 mL and 16.7, respectively, experienced shorter PFS (P = 0.016 and 0.002, respectively). Hence, these risk factors might be useful for selection of individuals likely to benefit from CAR T-cell therapy and their management.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Hemasphere Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Hemasphere Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha